|
David C. Stump joined the Company in November 1999 as Senior Vice President Drug Development. In December 2003 he was promoted to Executive Vice President. Dr. Stump came to HGS from Genentech Inc. where he was Vice President Clinical Research since 1995. In 1996 he was named a Genentech Fellow only the second in Genentech’s history. Dr. Stump also served as a member of the Genentech Product Development Committee and chaired the Clinical Review Committee. While he was closely involved with overall clinical development efforts during his last five years at Genentech Dr. Stump was most widely recognized for a decade of leadership of the company’s thrombolytic therapy drug development program which accomplished multiple successful clinical trials and drug approvals for patients with acute myocardial infarction and acute ischemic stroke. Dr. Stump joined Genentech in 1989 from the University of Vermont where he was Associate Professor of Medicine and Biochemistry. He holds an A.B. from Earlham College and an M.D. from Indiana University. Dr. Stump received residency and fellowship training in internal medicine hematology and oncology at the University of Iowa where he also received advanced research training in biochemistry. In addition he completed specialized training in hemostasis research as a visiting investigator at the University of Leuven Belgium. Dr. Stump is certified by the American Board of Medicine including its Medical Oncology and Hematology Subspecialty Boards. He holds membership in a variety of professional organizations and is an elected Fellow of the American College of Physicians and of the Council on Arteriosclerosis Thrombosis and Vascular Biology of the American Heart Association. Dr. Stump is a member of the Board of Trustees of Adventist HealthCare and the Board of Directors of Sunesis Pharmaceuticals Inc. | 